Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-4
- Development stage
- Unknown
- Lead developer
- China-Japan Friendship Hospital
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PRO-4 is a multi-strain probiotic formulation consisting of four specific bacterial strains: *Bifidobacterium lactis*, *Lactobacillus acidophilus*, *Lactobacillus casei*, and *Lactobacillus rhamnosus*. It is primarily being investigated by researchers at the China-Japan Friendship Hospital for its therapeutic potential in patients with chronic heart failure (CHF), particularly those with reduced ejection fraction (HFrEF). The rationale for its use is based on the "gut-heart axis" hypothesis, which suggests that heart failure is associated with gut dysbiosis and increased intestinal permeability, leading to systemic inflammation. PRO-4 aims to restore microbial balance, improve intestinal barrier function, and reduce the levels of pro-inflammatory cytokines and endotoxins, thereby potentially improving cardiac function and exercise tolerance.
- Brand names
- PRO-4PRO4PRO 4
Beyond the preview
Go deeper on PRO-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-4.